Mangalam Drugs & Organics Limited announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, the company reported sales/income from operations (net of excise duty) of INR 823.543 million compared to INR 607.834 million for the same period a year ago. Profit from operations before other income, finance cost and exceptional items was INR 77.429 million compared to INR 40.023 million for the same period a year ago. Profit before tax was INR 57.968 million compared to INR 12.948 million for the same period a year ago. Net profit was INR 37.968 million or INR 2.40 per diluted share before and after extraordinary items compared to INR 8.448 million or INR 0.64 per diluted share before and after extraordinary items for the same period a year ago.

For the nine months, the company reported sales/income from operations (net of excise duty) of INR 2,244.712 million compared to INR 1,401.908 million for the same period a year ago. Profit from operations before other income, finance cost and exceptional items was INR 200.528 million compared to INR 113.560 million for the same period a year ago. Profit before tax was INR 142.486 million compared to INR 32.474 million for the same period a year ago. Net profit was INR 104.986 million or INR 6.63 per diluted share before and after extraordinary items compared to INR 26.474 million or INR 2.01 per basic and diluted share before and after extraordinary items for the same period a year ago.